4.7 Article

Benchmarking Risk-Adjusted Adult Antibacterial Drug Use in 70 US Academic Medical Center Hospitals

期刊

CLINICAL INFECTIOUS DISEASES
卷 53, 期 11, 页码 1100-1110

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir672

关键词

-

资金

  1. UHC participating hospitals
  2. Merck
  3. Astellas
  4. Cubist

向作者/读者索取更多资源

Background. Antimicrobial stewardship programs are advised to measure and risk-adjust antimicrobial use to facilitate interhospital comparisons, a process called benchmarking. The purpose of this investigation was to evaluate a new benchmarking strategy for antibacterials. Methods. Hospital-wide adult antibacterial drug use in 2009 was measured as days of therapy (DOT) and length of therapy (LOT) from billing records in 70 US academic medical centers (AMCs). Patients were assigned to 1 of 35 clinical service lines (CSL) based on their Medicare Severity Diagnosis Related Group. Expected (E) use was determined by indirect standardization and compared with observed (O) use. Results. Of 1 791 180 discharged adults, 63.7% received antibacterial drugs; the range by CSL was 14.3% (psychiatry) to 99.7% (lung transplant). Mean +/- SD hospital-wide use was 839 +/- 106 DOTs (range, 594-1109) and 536 +/- 53.0 LOT (range, 427-684) per 1000 patient-days. The ventilator support CSL had the most DOT per discharge, 39.4 +/- 9.4 days; the LOT was 21.5 +/- 4.5 days. The hospital-wide O/E ratio range was 0.7-1.45; in 5 AMCs the ratio exceeded the 90% confidence interval (CI) and was below the 90% CI in 6. Variability in use was explained by the proportion of treated patients within each CSL and mean LOT and DOT per discharge. Conclusions. Adult antibacterial drug use was benchmarked to expected use adjusted for patient mix, and outlier hospitals were identified. Differences between expected and observed use reflect usage patterns that were benchmarked and are targets for evaluation and intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据